JP2023500953A5 - - Google Patents

Info

Publication number
JP2023500953A5
JP2023500953A5 JP2022526720A JP2022526720A JP2023500953A5 JP 2023500953 A5 JP2023500953 A5 JP 2023500953A5 JP 2022526720 A JP2022526720 A JP 2022526720A JP 2022526720 A JP2022526720 A JP 2022526720A JP 2023500953 A5 JP2023500953 A5 JP 2023500953A5
Authority
JP
Japan
Prior art keywords
polypeptide
vwf
erythrocyte
pharmaceutical composition
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526720A
Other languages
English (en)
Japanese (ja)
Other versions
JP7680442B2 (ja
JP2023500953A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081698 external-priority patent/WO2021094344A1/en
Publication of JP2023500953A publication Critical patent/JP2023500953A/ja
Publication of JP2023500953A5 publication Critical patent/JP2023500953A5/ja
Application granted granted Critical
Publication of JP7680442B2 publication Critical patent/JP7680442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526720A 2019-11-11 2020-11-11 第viii因子に対する寛容を誘導するためのポリペプチド Active JP7680442B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208259 2019-11-11
EP19208259.2 2019-11-11
PCT/EP2020/081698 WO2021094344A1 (en) 2019-11-11 2020-11-11 Polypeptides for inducing tolerance to factor viii

Publications (3)

Publication Number Publication Date
JP2023500953A JP2023500953A (ja) 2023-01-11
JP2023500953A5 true JP2023500953A5 (cg-RX-API-DMAC7.html) 2023-11-17
JP7680442B2 JP7680442B2 (ja) 2025-05-20

Family

ID=68531414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526720A Active JP7680442B2 (ja) 2019-11-11 2020-11-11 第viii因子に対する寛容を誘導するためのポリペプチド

Country Status (4)

Country Link
US (1) US20220348637A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058049A1 (cg-RX-API-DMAC7.html)
JP (1) JP7680442B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021094344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068504A2 (en) 2024-09-24 2026-04-02 The University Of Bristol Novel protein conjugates

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
BRPI0814220B8 (pt) 2007-07-11 2021-05-25 Novo Nordisk As purificação de fator viii usando uma resina multimodal ou de modo misto
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
PT2349342T (pt) 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
WO2010087271A1 (ja) 2009-01-28 2010-08-05 日本電気株式会社 不揮発ロジック回路
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
WO2011101284A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US9234192B2 (en) 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
WO2011131510A2 (en) 2010-04-21 2011-10-27 Novo Nordisk A/S Selective modification of proteins
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー/エス 安定化させた第viii因子バリアント
AU2011289579B2 (en) * 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
CA2864432A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US9879090B2 (en) 2013-03-04 2018-01-30 INSERM (Institut National De La SantéEt De La Recherche Médicale Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
WO2014198699A2 (en) 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
DK3164150T3 (da) * 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
JP2020504084A (ja) * 2016-11-16 2020-02-06 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 赤血球標的化第viii因子およびその使用方法
DK3641800T5 (da) * 2017-06-22 2024-08-26 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
WO2019075523A1 (en) 2017-10-20 2019-04-25 Csl Ltd. PROCESS

Similar Documents

Publication Publication Date Title
AU2020294797B2 (en) Multi-chain chimeric polypeptides and uses thereof
EP3844181B1 (en) Multi-chain chimeric polypeptides and uses thereof
EP3844182B1 (en) Single-chain and multi-chain chimeric polypeptides and uses thereof
CN103180339B (zh) 具有改善的稳定性的基于纤连蛋白的支架蛋白质
JP2024533311A5 (cg-RX-API-DMAC7.html)
JP2020515280A5 (cg-RX-API-DMAC7.html)
WO2022022718A1 (zh) 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途
US20220195009A1 (en) Hypoxia-responsive chimeric antigen receptors
JP2019536426A5 (cg-RX-API-DMAC7.html)
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2004508828A (ja) 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター(セレクトカイン)からの融合タンパク質
JP2020509737A5 (cg-RX-API-DMAC7.html)
WO2023125813A1 (zh) 抗间皮素纳米抗体嵌合抗原受体及其应用
WO2024008110A1 (zh) 抗ccr8抗体及其应用
JP2024023268A5 (cg-RX-API-DMAC7.html)
WO2026007560A1 (zh) 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN112048018A (zh) 一种嵌合t细胞生长因子及其应用
JP2020535811A5 (cg-RX-API-DMAC7.html)
WO2020253879A1 (zh) 一种双特异性嵌合抗原受体
Qin et al. Screening and anti‐glioma activity of Chiloscyllium plagiosum anti‐human IL‐13Rα2 single‐domain antibody
CN116253800B (zh) 一种抗cldn18.2的重链抗体、相关产品和用途
WO2024056097A1 (zh) 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
JP2020535832A (ja) マウス定常領域を伴うtcrを発現する細胞を選択的に増幅するための方法
CN106928365B (zh) 一种FAP纳米抗体Nb36
JP2024532760A (ja) 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用